Tempus CRC Surveillance Study: A Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Colorectal Cancer (CRC) Using Comprehensive Next-Generation Sequencing (NGS)Assays
Tempus AI
Summary
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Known or suspected colorectal adenocarcinoma (Stage I to IVA disease) * Planning to undergo or has undergone a surgical resection for suspected adenocarcinoma of the colon or rectum with curative intent. * 18 years old or older * Willing and able to provide informed consent * Willing to have additional blood samples collected during routine surveillance visits Exclusion Criteria: * Not willing to have additional blood samples collected * Pathology that is not consistent with colorectal adenocarcinoma
Interventions
- OtherObservation
No intervention
Locations (20)
- Mercy Clinic Oncology - Fort SmithFort Smith, Arkansas
- MemorialCareFountain Valley, California
- The Center for Cancer and Blood DisordersBethesda, Maryland
- Mercy Clinic Oncology and Hematology - JoplinJoplin, Missouri
- Mercy Clinic Cancer and Hematology - Chub O'Reilly Cancer CenterSpringfield, Missouri
- Washington University School of MedicineSt Louis, Missouri